Alector, Inc.（ALEC）資訊與事件ALECAlector, Inc.

Alector Prices 36.6M Common Stock Offering at $2.05

Alector announced the pricing of an underwritten offering of common stock. Alector is selling 36.6M shares of common stock. The shares of common stock are being sold at an offering price of $2.05 per share, which represents a premium of approximately 7.3% over the closing price on October 15. The gross proceeds to Alector from this offering are expected to be $75.03M before deducting the underwriting discounts and commissions and other estimated offering expenses. All shares of common stock to be sold in the offering are being offered by Alector. The offering is expected to close on or about October 19, subject to the satisfaction of customary closing conditions. The financing includes participation from new and existing investors, including TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital, among others. Morgan Stanley & Co. and BTIG are acting as joint lead book-running managers for the offering.

Alector Enters Exclusive Licensing Agreement with Genentech

Alector (ALEC) announced it has entered into an exclusive global licensing agreement with Genentech, a member of Roche (RHHBY), granting Genentech worldwide rights to develop and commercialize Alector's AL050 program, its brain-penetrant engineered glucocerebrosidase ERT. AL050 is designed to address GCase deficiency, a driver of neurodegeneration in Parkinson's Disease that is most pronounced in - but not limited to - carriers of GBA1 mutations. It combines an Alector-engineered GCase, optimized for greater enzymatic activity and a longer half-life, with Alector's ABC, which is designed to transport therapeutics across the blood-brain barrier. Delivered into the brain, the enzyme is intended to break down glucosylsphingosine and glucosylceramide, lipids that accumulate in neurons and other brain cells upon GCase deficiency and contribute to neurodegeneration, with the aim of reducing cellular dysfunction and slowing disease progression. Under the terms of the agreement, Alector will receive an upfront payment of $100M and is also eligible to receive additional payments of up to $1.17B upon the achievement of development, regulatory, and commercial milestones. Alector is also eligible for tiered royalties on net sales. Under the collaboration, Genentech will be responsible for development, regulatory, manufacturing, and commercialization across all indications. Alector retains ownership of ABC and full rights to apply the platform across its wholly owned pipeline.

Alector Reports Q2 Revenue of $3.32M, Beating Consensus

Reports Q2 revenue $3.32M, consensus $1.71M. "We continue to make steady progress across our ABC-enabled preclinical and research pipeline," said Arnon Rosenthal, Chief Executive Officer of Alector. "Our work across antibodies, enzymes, and siRNA reflects the versatility of the ABC platform and our strategy to apply it to programs where enhanced brain delivery may address important limitations in the treatment of neurodegenerative diseases. We remain focused on disciplined execution as we advance our portfolio toward clinical development, with the goal of addressing important unmet needs for patients living with neurodegenerative diseases."